Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A global Phase 3 registrational trial of vebicorvir

X
Trial Profile

A global Phase 3 registrational trial of vebicorvir

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 22 Jul 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Vebicorvir (Primary)
  • Indications Hepatitis B
  • Focus Registrational; Therapeutic Use
  • Sponsors Assembly Biosciences
  • Most Recent Events

    • 20 Jul 2022 According to an Assembly Biosciences media release, the company has discontinued development of vebicorvir based on interim efficacy data from ongoing combination clinical studies.
    • 20 Jul 2022 Status changed from planning to discontinued, according to a Assembly Biosciences media release.
    • 25 Feb 2021 According to an Assembly Biosciences media release, the decision to not initiate the global registrational studies of VBR as CST followed extensive discussions with leading experts in the field and regulatory agencies, and with respect to the China territory, discussions and agreement with the company partner, BeiGene, Ltd. The study is expected to begin in 2023.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top